LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.

MiniMed Group, the diabetes business of Medtronic, filed Tuesday to raise up to $784 million in an initial public offering. The Northridge, California-based firm p ...

InnovaMatrix revenue is expected to fall to approximately $20 million in 2026 from $69 million in 2025, a decline of roughly 71%, representing a headwind of approximately 2% of group revenue.

Feel tired, foggy, or irritable after eating? Learn how blood sugar spikes can happen even with a normal A1C — and what to do about them.

The scientists will develop the Human Flatus Atlas, which quantifies the dynamic range of intestinal gas production. Read ...

By the time cancer symptoms appear, the disease has already been developing for years, often leaving subtle clues in routine bloodwork long before diagnosis.

Scientists have long known that people living at high altitudes, where oxygen levels are low, have lower rates of diabetes than people living closer to sea level. But the mechanism of this protection ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Notice: By accessing this site you agree that you will not copy or reproduce any part of its contents (including, but not limited to, single prices, graphs or news content) in any form or for any ...

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Netherlands: Spending office hours in natural daylight rather than under artificial lighting may improve glucose regulation and metabolic health in people with type 2 diabetes (T2D), a study published ...